Acute HIV Studies at UNC
CID 0804: Longitudinal (CTRC 2134) – Acute HIV Longitudinal Study
|POP:||Individuals diagnosed with Acute HIV Infection|
|CALL:||Francesca Prince, 919-966-8794 or 919-428-7612 or Caroline Baker, 919-966-2623|
PHI 05: QD Therapy with Dolutegravir/Epzicom for Acute HIV Infection
|Q:||Treatment of Acute HIV Infection with one tablet once a day|
|POP:||Acute HIV infection|
|MED:||Fixed-dose combination of dolutegravir and epzicom
|DUR:||5 years (medication provided for 2 years)|
|CALL:||Kristen Hancock, RN, 919-843-6848|
A5354: Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Timing of antiretroviral therapy (ART) during different stages of acute HIV-1 infection (AHI) will be predictive of the magnitude and characteristics of HIV-1 reservoirs, and the quantity and quality of HIV-1-specific immune responses at week 48.
Men and women 18 years and older with AHI.
Group 1: Fiebig I/II (non-reactive HIV-1 antibody)
Group 2: Fiebig III/IV (reactive HIV-1 antibody and negative or indeterminate results on the Western blot or Geenius HIV-1/HIV-2)
Group 3: Fiebig V (reactive HIV-1 antibody and positive Western blot or Geenius HIV-1/HIV-2 without p31 band)
The antiretroviral (ARV) regimen provided through the study is the single tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF). Other non-study-provided ARV regimens will be allowed for participants who are pregnant, breastfeeding, or unable/unwilling to take EVG/COBI/FTC/TAF, or for participants whose local health care/primary care provider prefers starting a different initial ARV regimen.
Up to 72 weeks.
Kristen Hancock, RN, BSN, 919-843-6848 or Susan Pedersen, RN, 919-966-6713